TriReme Medical Lines Up Asian Strategy With Key Appointment of New Board Members

Wednesday, May 11, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

PLEASANTON, Calif., May 9, 2011 /PRNewswire/ -- TriReme Medical, Inc. (TriReme), a leading developer of innovative catheters

and stents for the treatment of complex vascular disease, announced today the appointment of Mr. Supratim Bose and Mr. Michael Kleine to their Board of Directors.

Mr. Bose, Founder

and CEO of Bose Consulting Group, is based in Singapore and was until recently Company Group Chairman at Johnson & Johnson with responsibilities for all of the Medical Devices & Diagnostics franchises across the Asia-Pacific Region.  Mr. Bose was also a member of the Worldwide Group Operating Committee at Johnson & Johnson Medical Devices & Diagnostics Group.

Mr. Kleine was previously President and CEO of Biosensors International (SGX), a medical device company listed on the Singapore Stock Exchange.  He brings vast experience in medical devices having held CEO and President positions at Microvention, Thermo Cardiosystems, Sorin Biomedical and Bird Medical.

"TriReme is developing an exciting range of innovative and differentiated devices and I am excited to help lead their Asian centered strategy," commented Mr. Bose.  Mr. Kleine added, "TriReme has created a truly global vision and its expansion is supported by a strong pipeline of unique products."

"Supratim and Mike's enormous experience with the Asian markets provide an extended dimension to both our Board and management teams.  TriReme is honored to have the endorsement of both industry veterans who support and share our global vision of medtech growth and development in Asia," said Eitan Konstantino, PhD, President and Chief Executive Officer of TriReme.

About TriReme Medical, Inc.

Based in Pleasanton, California, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The Company's novel balloon and stent therapies are specifically designed for large, unmet clinical needs.

SOURCE TriReme Medical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store